Mitomycin C and menadione for the treatment of lung cancer: a phase II trial

@article{Tetef2004MitomycinCA,
  title={Mitomycin C and menadione for the treatment of lung cancer: a phase II trial},
  author={Merry L. Tetef and Kim A Margolin and Chul Ahn and Steven A. Akman and Warren A. Chow and Lucille A. Leong and Robert J. Jr. Morgan and James W. Raschko and George Somlo and James H. Doroshow},
  journal={Investigational New Drugs},
  year={2004},
  volume={13},
  pages={157-162}
}
SummaryA phase II trial of menadione [2.5 gm/m2 as a continuous intravenous (iv) infusion over 48 hours] followed by mitomycin C (10–20 mg/m2 iv bolus) administered every 4 to 6 weeks was performed in 23 patients with advanced lung cancer. Menadione, a vitamin K analog which lowers intracellular pools of reduced glutathione (GSH), was combined with mitomycin C in an attempt to overcome thiol-mediated resistance to alkylating agent chemotherapy. The median age of patients entered on this trial… 

Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy

A phase I trial of M in patients with advanced cancer with median patient age, Karnofsky performance status, and number of prior chemotherapy regimens, finding no objective partial or complete responses was observed.

Phase I clinical trial of i.v. ascorbic acid in advanced malignancy.

  • L. HofferM. Levine W. Miller
  • Medicine, Biology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2008
High-dose i.v. ascorbic acid was well tolerated but failed to demonstrate anticancer activity when administered to patients with previously treated advanced malignancies, suggesting the promise of this approach may lie in combination with cytotoxic or other redox-active molecules.

Cytotoxic effect of menadione and sodium orthovanadate in combination on human glioma cells

The results indicate that M:SO combination is an attractive alternative for glioma treatment that encourages further study and suggests a role of oxidative stress and tyrosine kinase stimulation in the M:so cytotoxic effect.

The In Vitro and In Vivo Antitumor Activity of Vitamin C: K3 Combinations Against Prostate Cancer

Experimental animal studies indicate that autoschizis is also evident when the vitamin combination is administered to nude mice with implanted human prostate tumors, suggesting that the Vitamin C and vitamin K3 combination may offer great potential as a new antitumoral chemotherapy.

The potentiation of menadione on imatinib by downregulation of ABCB1 expression

Menadione improved imatinib efficacy in K562 cells by downregulating ABCB1 expression and increased the intracellular concentration ofImatinib, which confirmed that this combination regimen is more effective than imatinIB monotherapy.

Vitamin C and K3 Combination Causes Enhanced Anticancer Activity against RT-4 Bladder Cancer Cells

VC:VK3 was able to cause autoschizic cell death through oxidative stress, thiol depletion, lipid peroxidation, modification of ATP levels and calcium regulation, and was granted orphan drug status for the treatment of metastatic or locally advanced, inoperable transitional cell carcinoma of the urothelium.

Menadione reduces CDC25B expression and promotes tumor shrinkage in gastric cancer

Menadione was able to reduce migration, invasion and proliferation rates, and induce cell cycle arrest in gastric cancer cell lines, and suggest this compound may be an important ally of chemotherapeutics in the treatment of Gastric cancer.

Avaliação do efeito citotóxico de piranonaftoquinonas inibidoras de DNA topoisomerases sobre células de leucemia

New topoisomerase inhibitors derived from α and β-lapachone (PNQs) were evaluated as to their potential cytotoxic effect on leukemia cells through viability, apoptosis and cellular cycle, and indicated a partial dependency of the Fas pathway activation for the action of these PNQs.

Schisandrin B protects against menadione-induced hepatotoxicity by enhancing DT-diaphorase activity

The ensemble of results suggests that the ability of Sch B pretreatment to enhance hepatocellular DTD activity may at least in part be attributed to the protection against menadione hepatotoxicity.

References

SHOWING 1-10 OF 21 REFERENCES

A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C

It is suggested that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m−2 or more, mainly in patients also treated with doxorubicin, and the incidence is likely to be less than 10% even for this risk group.

Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium.

  • J. DoroshowL. Leong E. Newman
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1989
The results suggest that augmentation of the reduced folate levels of metastatic breast carcinomas may enhance the effectiveness of the fluoropyrimidines in this disease.

Selective enhancement by menadiol of in vitro drug activity in human lymphatic neoplasms.

Cell survival times with mechlorethamine, vincristine, and dexamethasone were converted from a range characteristic of drug resistance to a range of drug sensitivity in the presence of menadiol, which is probably clinically achievable.

Vitamin K in the treatment of cancer.

Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry.

Recommendations include careful monitoring of renal and hematologic function in patients treated with MMC, aggressive nontransfusion in patients with suspected C-HUS, and consideration of treatment with SPA immunopheresis in Patients with definite syndrome.

Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor.

The use of G-CSF results in a more than twofold increase in the MTD of piroxantrone, however, symptomatic cardiotoxicity is prominent, especially in patients who have received prior treatment with anthracyclines.

New findings in the pharmacokinetic, metabolic, and drug-resistance aspects of mitomycin C.

  • R. Dorr
  • Biology, Chemistry
    Seminars in oncology
  • 1988
There was no evidence of dose dependent pharmacokinetics over a wide range of doses and patient populations, including pediatric solid tumor patients, and new observations of the development of the multidrug-resistance phenotype in mitomycin C-treated L-1210 cells in vitro.

Synergistic cytotoxicity between menadione and dicumarol vs. murine leukemia L1210.

Isobolographic analysis of the effect of K3-dicumarol combinations, in the concentration ranges between 5 and 75 microM, on L1210 growth, indicated synergy between the two drugs, and it was possible that effects on the glutathione and/or NADPH pools contributed.

Evaluation of piroxantrone in women with metastatic breast cancer and failure on nonanthracycline chemotherapy

The anthrapyrazoles, of which piroxantrone is a member, were synthesized in an attempt to eliminate this toxicity of doxorubicin.